Cytosorbents Corporation (CTSO) Earning Somewhat Positive Press Coverage, Analysis Finds
News headlines about Cytosorbents Corporation (NASDAQ:CTSO) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytosorbents Corporation earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.504148212721 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s analysis:
- Cytosorbents Corporation (CTSO) to Post Q1 2018 Earnings of ($0.10) Per Share, B. Riley Forecasts (americanbankingnews.com)
- Cytosorbents Corporation (CTSO) Rating Reiterated by B. Riley (americanbankingnews.com)
- CytoSorbents Recognized on Deloitte’s 2017 Technology Fast 500™ as One of the Fastest Growing Companies in … – PR Newswire (press release) (prnewswire.com)
- Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
- Cytosorbents Corporation (CTSO) Given “Buy” Rating at Maxim Group (americanbankingnews.com)
Shares of Cytosorbents Corporation (NASDAQ:CTSO) opened at $6.25 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36. Cytosorbents Corporation has a twelve month low of $3.30 and a twelve month high of $6.70.
CTSO has been the subject of a number of research reports. Aegis reaffirmed a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. ValuEngine raised Cytosorbents Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Maxim Group set a $12.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a report on Thursday, October 19th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, September 26th. Finally, B. Riley reaffirmed a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a report on Friday. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $10.45.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.